Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
Status:
New, Temporarily Closed
A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
NCT#03609216
Due to laboratory requirements necessitating the collection of additional information for genomic testing from all participating patients, A031701 is temporarily suspended, effective immediately, 04/11/19. An updated protocol and informed consent will be forthcoming.
